Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ReproCELL Incorporated (4978.T)
Yokohama, JP
Established in 2003 and headquartered in Yokohama, Japan, ReproCELL Incorporated operates as a prominent firm specializing in stem cell research. The company furnishes an extensive portfolio of products crucial for various stem cell applications, including a diverse array of specialized reagents for RNA reprogramming, cell growth (such as small molecules, growth factors, and cytokines), cell characterization (like antibodies and staining kits), cell culture (including pluripotent stem cell media and cell substrates), and cell handling (such as cryopreservation media, dissociation solutions, and transfection reagents). Furthermore, ReproCELL provides differentiated induced pluripotent stem cells (iPSCs), related components like feeder cells and induced neurons, 3D cell culture systems, and general laboratory consumables. Complementing its product lines, the company offers a comprehensive suite of services, spanning preclinical genomics, dedicated stem cell research, drug development support (encompassing efficacy, safety, and ADME analyses), access to human tissue samples, therapeutic pipeline development, and a range of clinical services, including laboratory diagnostics and the creation of GMP iPSC master cell banks.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.28% | -10.92% | -13.89% | -3.73% | -1.27% | +6.16% | +1.31% | -47.46% | -61.82% | -64.69% | -94.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-25.0% Q1'26: -31.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-663.1% Q1'26: -198.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-32.3% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-38.5% Q1'26: -29.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-36.8% Q1'26: -31.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+2.0% ★ Q1'26: +0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.07B
est: 1.05B (+1.6%)
|
1.26B
est: 1.18B (+6.6%)
|
926.26M
est: 920.00M (+0.7%)
|
1.09B
est: 1.20B (-9.3%)
|
1.20B
est: 1.20B (0.0%)
|
1.29B
est: 1.29B (-0.3%)
|
2.23B
est: 2.06B (+8.5%)
|
2.95B
est: 2.81B (+5.1%)
|
2.43B
est: 2.63B (-7.7%)
|
2.98B
est: 2.88B (+3.4%)
|
3.17B
3.17B – 3.17B
+10.1% YoY
|
3.53B
3.53B – 3.53B
+11.4% YoY
|
| EBITDA |
-698.61M
est: -177.49M (-293.6%)
|
-689.16M
est: -199.46M (-245.5%)
|
-772.30M
est: -155.51M (-396.6%)
|
-704.77M
est: -202.85M (-247.4%)
|
-818.74M
est: -202.85M (-303.6%)
|
-962.63M
est: -218.06M (-341.5%)
|
-587.37M
est: -348.22M (-68.7%)
|
-307.23M
est: -475.00M (+35.3%)
|
-372.18M
est: -681.37M (+45.4%)
|
-79.70M
est: -517.55M (+84.6%)
|
-569.66M
-569.66M – -569.66M
-10.1% YoY
|
-634.35M
-634.35M – -634.35M
-11.4% YoY
|
| EBIT |
-1.02B
est: -207.32M (-394.1%)
|
-944.30M
est: -232.99M (-305.3%)
|
-1.03B
est: -181.65M (-464.7%)
|
-781.12M
est: -236.94M (-229.7%)
|
-908.94M
est: -236.94M (-283.6%)
|
-1.05B
est: -254.71M (-311.5%)
|
-647.13M
est: -406.74M (-59.1%)
|
-356.22M
est: -554.83M (+35.8%)
|
-409.29M
est: -756.09M (+45.9%)
|
-130.41M
est: -580.45M (+77.5%)
|
-638.90M
-638.90M – -638.90M
-10.1% YoY
|
-711.45M
-711.45M – -711.45M
-11.4% YoY
|
| Net Income |
-1.96B
est: -3.31B (+40.7%)
|
-911.66M
est: -1.26B (+27.5%)
|
-2.17B
est: -3.16B (+31.3%)
|
-601.43M
est: -1.06B (+43.2%)
|
-1.02B
est: -1.31B (+22.6%)
|
-812.57M
est: -1.23B (+34.1%)
|
-575.10M
est: -419.69M (-37.0%)
|
-305.31M
est: -76.14M (-301.0%)
|
-31.42M
est: -283.20M (+88.9%)
|
103.25M
est: 33.14M (+211.5%)
|
75.76M
75.76M – 75.76M
+128.6% YoY
|
160.99M
160.99M – 160.99M
+112.5% YoY
|
| SGA |
977.86M
est: 483.96M (+102.1%)
|
1.01B
est: 543.87M (+85.8%)
|
980.83M
est: 424.04M (+131.3%)
|
969.77M
est: 553.09M (+75.3%)
|
887.45M
est: 553.09M (+60.5%)
|
842.11M
est: 594.57M (+41.6%)
|
897.26M
est: 949.47M (-5.5%)
|
982.41M
est: 1.30B (-24.1%)
|
1.13B
est: 1.19B (-5.2%)
|
1.22B
est: 1.25B (-2.0%)
|
1.37B
1.37B – 1.37B
+10.1% YoY
|
1.53B
1.53B – 1.53B
+11.4% YoY
|
| EPS |
-36.16
est: -35.60 (-1.6%)
|
-15.68
est: -13.54 (-15.8%)
|
-34.28
est: -34.03 (-0.7%)
|
-8.79
est: -11.40 (+22.9%)
|
-14.27
est: -14.14 (-0.9%)
|
-11.38
est: -13.28 (+14.3%)
|
-7.57
est: -4.52 (-67.5%)
|
-3.62
est: -0.82 (-341.5%)
|
-0.37
est: -3.05 (+87.9%)
|
1.11
est: 0.35 (+217.1%)
|
0.80
0.80 – 0.80
+128.6% YoY
|
1.70
1.70 – 1.70
+112.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P International Small Cap ETF GWX | 0.00% | 39.9K | 0.40% |
| 2 | State Street SPDR Portfolio Developed World ex-US ETF SPDW | 0.00% | 622.0K | 0.03% |
| 3 | Dimensional - International Core Equity 2 ETF DFIC | 0.00% | 19.3K | 0.22% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chikafumi Yokoyama | Chief Executive Officer, President & Representative Director | — | — |
| Daisuke Usui | Chief Operating Officer & Director | — | male |
| David Bunton | Chief Executive officer of REPROCELL Europe | — | — |
| Hiroshi Yagi | Advisor & Founder | — | male |
| Hiroyuki Mizuguchi | Advisor & Founder | — | male |
| Ramakrishna V. Modali | Chief Executive Officer of REPROCELL USA Inc. | — | male |
| Satoshi Munemura | CFO & GM of Business Administration Dept. | — | — |
| Shuji Yokoyama | Chief Executive Officer, President & Representative Director | — | — |
| Stefan A. Przyborski | CSO of REPROCELL Europe Ltd. | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4978.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
